3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
2
Gastrointestinal
2
Dermatologic
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
CNS
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Precancerous Conditions
1
Interventions
Paclitaxel
108
Carboplatin
96
pembrolizumab
63
Cisplatin
62
Cyclophosphamide
44
Bevacizumab
35
Taxes
31
Gemcitabine
28
liposomal doxorubicin
27
Topotecan
26
fludarabine
24
olaparib
22
Nivolumab
20
Docetaxel
20
Radiotherapy
18
Brachytherapy
17
veliparib
16
Magnetic Resonance Spectroscopy
16
Doxorubicin
16
Biopsy
15
Radiation
14
niraparib
13
aldesleukin
13
Specimen Handling
13
Platinum
13
Oxaliplatin
13
Filgrastim
13
Albumin-Bound Paclitaxel
12
atezolizumab
11
Interleukin-2
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Microarray Analysis
×
Gynecologic
×
Clear all
NCT00629577
2017-02-01
SAGE
British Columbia Cancer Agency
Phase 1
Terminated
50 enrolled